Clinical trial
Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis…
NCT00258011 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00258011 |
|---|---|
| Title | Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease |
| Official title | A Safety Confirmatory Study of JC0498 (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | BioMarin/Genzyme LLC Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Mucopolysaccharidosis I, Hurler Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome |
| Intervention type | Biological |
| Interventions | Aldurazyme (Recombinant Human Alpha-L-Iduronidase) |
| Enrollment | 3 |
| Start date | Dec 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Nov 24, 2005 |
| Last update posted | Mar 7, 2014 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: